News

A recent study published in Circulation shows that patients who take their medication faithfully have dramatically better long-term outcomes, regardless of whether they have CABG or PCI. However, among the non-adherent group, CABG patients fared better with fewer major adverse cardiac events in the years after surgery.
“This study shows how important it is to get to know your patients and find out how well they comply with medication,” says Paul Kurlansky, MD, who led the study and is currently director of research for Columbia HeartSource.
Read More
NYP/Columbia was among the first to offer patients access to Heartmate 3, the newest LVAD technology, in a clinical trial testing it against current standard of treatment, the Heart Mate II.
In a randomized study reported in New England Journal of Medicine and presented at American Heart Association in November 2016, lead investigator Yoshifumi Naka, MD, PhD, reported fewer complications with the Heartmate 3, noting a marked improvement over Heartmate II.
Read More
NULL
The Structural Heart and Valve Center at NYP/Columbia has long been a leader in catheter-based treatment—the least invasive therapy—to repair the mitral valve. This valve regulates blood flow between the upper and the lower chambers on the left side of the heart. When it is damaged or defective, blood flows back up into the upper chamber, producing Mitral Regurgitation (MR).
Read More